Showing 41-50 of 132 results for "".
Patient-Centered Wound Healing
https://practicaldermatology.com/topics/feature/patient-centered-wound-healing/26645/Patient-Centered Wound HealingDermWireTV: Ped Derm Salaries; Skin Cancer Symposium Kicks Off; Pandemic Self Care Stats
https://practicaldermatology.com/topics/practice-management/dermwiretv-ped-derm-salaries-skin-cancer-symposium-kicks-off-pandemic-self-care-stats/19910/According to the Society for Pediatric Dermatology’s 2020 Pediatric Dermatology Physician Compensation Report, salaries have increased 37% since 2014. Pediatric dermatologist Mercedes Gonzalez, MD comments. The inaugural Skin Cancer Symposium is underway and the Symposium for Inflammatory Disease kiJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseSCALE 2019: Meeting Highlights from Music City
https://practicaldermatology.com/topics/practice-management/scale-2019-meeting-highlights-from-music-city/19619/With an emphasis on both medical and cosmetic dermatology as well as practice management, Music City Scale or the Symposium for Cosmetic Advances and Laser Education has something for everyone, organizers says. Co-chairs Michael Gold, MD and Brian Biesman, MD are joined by several presenters to discJournal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EJournal Club: Updated Clinical Practice Guidelines
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-updated-clinical-practice-guidelines/32316/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with new Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, about the updated clinical practice guidelines for atopic dermatitis published in the Journal of Dermatology in December.Saeki H, et alJournal Club: Tapinarof Cream in Pediatric Patients
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-tapinarof-cream-in-pediatric-patients/32399/Practical Dermatology Editorial Board member Peter Lio, MD, speaks with Mona Shahriari, MD, about the Journal of Dermatology article "A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis," and the general importance ofDr. Goldberg Discusses Experience with the VariLite Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-goldberg-discusses-experience-with-gemini-laser/19468/“One of the great things about being in the laser field is there are new lasers that come out every day. It makes it a very exciting arena to be in. The problem is the popular machine of today, unfortunately, often becomes the machine that you don't need a year from now. The VariLite is tried andAnalyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versu- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select